Unlike common nutraceuticals stocked in every health store, CJC-1295 moves through a specialist research supply market that Salal residents reach through online vendors. What this means for Salal researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those evaluation tools are available to every researcher. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. This guide walks Salal researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Salal researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
The most consistent path to quality CJC-1295 is community research first — peptide forums track vendor quality over time that are more reliable than search results. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. The combination of community reputation data and your own COA analysis is the most reliable sourcing approach — community feedback surfaces patterns individual COA review misses, and vice versa. The powdered lyophilised form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations degrade within weeks even when refrigerated.
Order CJC-1295 — ships to Salal
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not approved for human use and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
